Clinical Trial Detail

NCT ID NCT02071862
Title Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Calithera Biosciences, Inc
Indications

lung non-small cell carcinoma

gastrointestinal stromal tumor

triple-receptor negative breast cancer

renal cell carcinoma

malignant mesothelioma

Advanced Solid Tumor

Therapies

CB-839 + Everolimus

CB-839 + Erlotinib

CB-839 + Docetaxel

CB-839

CB-839 + Paclitaxel

Cabozantinib + CB-839

Age Groups: adult senior

Additional content available in CKB BOOST